Interview with Thomas Powles: The use of durvalumab in urothelial cancer - the latest strides in immuno-oncology.

Interview with Thomas Powles: The use of durvalumab in urothelial cancer - the latest strides in immuno-oncology.

Future Oncol. 2017 Jul 20;:

Authors: Powles T

Abstract
Thomas Powles speaks to Sebastian Dennis-Beron, Commissioning Editor: Dr. Thomas Powles is a clinical professor of genitourinary oncology and the lead for solid tumor research at Barts Cancer Institute in London. His main research interests are in genital and urinary cancers, in which he leads a spectrum of clinical studies from Phase I to randomized Phase III investigating novel targeted and immune therapies. His research also focuses on correlation of novel biomarkers and aims to define markers with prognostic value that may predict response or resistance to therapy. Dr. Powles is the author of more than 100 publications, on the editorial board of a number of journals, and part of the faculty for multiple global oncology meetings. He qualified from St Bartholomew's Medical School and received his MD from the University of London.

PMID: 28726491 [PubMed - as supplied by publisher]

from # & - All via ola Kala on Inoreader http://ift.tt/2uG0mTI